Firategrast for relapsing remitting multiple sclerosis: A phase 2, randomised, double-blind, placebo-controlled trial

The Lancet Neurology

Volumn 11, Issue 2, 2012, Pages 131-139

  Miller, David H ^a   Weber, Thomas ^d   Grove, Richard ^e   Wardell, Claire ^e   Horrigan, Joseph ^f   Graff, Ole ^g   Atkinson, Gillian ^g   Dua, Pinky ^h   Yousry, Tarek ^c   MacManus, David ^b   Montalban, Xavier ⁱ  

^a Department of Neuroinflammation ^*  (United Kingdom)

^b NMR Research Unit   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF HAMBURG   (Germany)

^e GLAXOSMITHKLINE   (United Kingdom)

^f Autism Speaks Inc   (United States)

^g GLAXOSMITHKLINE   (United States)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIRATEGRAST; GADOLINIUM; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; BINOMIAL DISTRIBUTION; BRAIN DAMAGE; BRAIN SCINTISCANNING; BRONCHITIS; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; EROSIVE GASTRITIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INFLUENZA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CYST; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; RHINOPHARYNGITIS; SEX; STATISTICAL MODEL; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; VERTIGO; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; INTEGRIN ALPHA4BETA1; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; TREATMENT OUTCOME;

EID: 84856015884     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70299-X     Document Type: Article

References (28)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. The IFNB Multiple Sclerosis Study Group.
2. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis:results of a phase III multicentre, double-blind, placebo-controlled trial. Neurology 1995, 45:1268-1275.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294.
4. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504. Prisms (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
5. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
6. Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801. CAMMS223 Trial Investigators.
7. Ellis R, Boggild M , Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it?. Mult Scler 2009, 15:505-508.
8. Polman CH, O'Connor PW, Havrdova E, et al. A randomised, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. NEJM 2006, 354:899-910.
9. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924-933.
10. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9:438-446.
11. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
12. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
13. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15-23.
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald Criteria" Ann Neurol 2005, 58:840-846.
15. Kurtze JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
16. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel of the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
17. Zink RC, Koch GG SAS macro NparCov Version 2. Non parametric analysis of covariance 2002, University of North Carolina, Chapel Hill.
18. Julious SA Using confidence intervals around individual means to assess statistical significance between two means. Pharmaceut Statist 2004, 3:217-222.
19. Statistical principles for clinical trials: ICH harmonized tripartite guideline. Stat Med 1999, 18:1905-1942. ICH E9 Expert Working Group.
20. Rice G, Hartung S, Calabresi P Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005, 64:1336-1342.
21. Kamisako T, Kobayashi Y, Takeuchi K, et al. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J Gastroenterol 2000, 35:659-664.
22. Reuben A Hy's law. Hepatology 2004, 39:574-578.
23. Comi G, Filippi M, Wolinsky JS European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001, 49:290-297.
24. Gorelik L, Lerner M, Bixler S, et al. Anti-JC Virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:295-303.
25. Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009, 27:767-771.
26. de Witte L, Bobardt M, Chatterji U, et al. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci USA 2007, 104:19464-19469.
27. Wollebo HS, Safak M, Del Valle L, Khalili K, White MK Role for tumor necrosis factor-alpha in JC virus reactivation and progressive multifocal leukoencephalopathy. J Neuroimmunol 2011, 233:46-53.
28. Full prescribing information FDA, (accessed Oct 2, 2011). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125104s0658lbl.pdf.